Loading
Prostate Cancer Treatment and Research / Prostate Cancer Diagnosis and Treatment / Neuroendocrine Tumor Research Advances · Journal article
Journal of Clinical and Diagnostic Research · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single case report of a 66-year-old man with metastatic neuroendocrine prostate cancer treated with cisplatin, etoposide, radiotherapy and second-line chemotherapy who remained asymptomatic on follow-up. The case illustrates a rare aggressive variant and suggests that multimodal therapy may improve symptom control, but provides no quantified survival, response rate, or comparative evidence.
Single case report. One 66-year-old male with metastatic neuroendocrine prostate adenocarcinoma with involvement of lymph nodes, liver, and bones.. Intervention: Cisplatin and etoposide chemotherapy, palliative radiotherapy, whole brain radiotherapy, and second-line systemic chemotherapy..
66-year-old male with metastatic adenocarcinoma of prostate with neuroendocrine differentiation presented with normal PSA level despite extensive metastatic disease in lymph nodes, liver and bones Patient treated with cisplatin and etoposide chemotherapy plus palliative radiotherapy, then whole brain radiotherapy and second-line chemotherapy for brain and bony metastases Patient tolerated treatment well and remained asymptomatic on follow-up
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This case illustrates that neuroendocrine prostate cancer can present with normal PSA levels despite advanced metastatic disease, and that aggressive multimodal therapy (chemotherapy and radiotherapy) may be tolerable and provide symptom control. However, no survival duration, response metrics, or prognostic conclusions can be drawn from one case.
A single case report with clinical follow-up data; no control group, no outcome quantification beyond descriptive narrative, and no generalizable evidence for efficacy.
As stated by the source record.
Quoted from the source exactly as published.
This case illustrates that neuroendocrine prostate cancer can present with normal PSA levels despite advanced metastatic disease, and that aggressive multimodal therapy (chemotherapy and radiotherapy) may be tolerable and provide symptom control. However, no survival duration, response metrics, or prognostic conclusions can be drawn from one case.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Neuroendocrine (NE) prostate cancer is a rare and aggressive variant of prostate carcinoma, often presenting in advanced stages with widespread metastases and is associated with poor prognosis and limited treatment options. Hereby, the authors present the case of a 66-year-old male initially diagnosed with metastatic adenocarcinoma of the prostate with NE differentiation. Despite a normal Prostate-Specific Antigen (PSA) level, extensive metastatic disease involving lymph nodes, liver and bones was identified. The patient was treated with systemic chemotherapy (cisplatin and etoposide) and palliative radiotherapy. Subsequent progression led to brain metastases and bony metastasis, which were managed with whole brain radiotherapy and systemic second line chemotherapy. The patient tolerated treatment well and remains asymptomatic on follow-up. NE prostate cancer is a rare and aggressive entity with limited therapeutic options. Normal PSA levels in the setting of advanced disease should raise suspicion for NE differentiation. Early diagnosis and aggressive multimodal therapy, including high-dose radiotherapy, may improve symptom control and prolong survival in selected patients.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.